Drug Profile
MP 124
Alternative Names: MP-124Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Stroke in USA (IV, Infusion)
- 21 Feb 2018 Phase-I development is ongoing in USA (Mitsubishi Tanabe pipeline, February 2018)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Stroke in USA (IV, Infusion)